ERBB2 and neoplasm: The results showed longer progression-free and overall survival with TDXd than with the physician's choice of chemotherapy.(7) Subsequently, researchers performed the Destiny-Pan Tumor02 trial to assess the efficacy of T-DXd in patients with HER2-expressing tumors, irrespective of the tumor site of origin.